RPAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RPAY is not a good buy right now. The chart is in a bearish trend (SMA_200 > SMA_20 > SMA_5, MACD still negative), fundamentals in the latest quarter (2025/Q3) weakened, and Wall Street has been cutting price targets after Q3. With no bullish proprietary signals today and negative near-term pattern odds (next week/month skew negative), the risk/reward does not fit an impatient buyer—better to avoid new entries at current levels.
Trend and momentum remain bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a persistent downtrend rather than a reversal. MACD histogram is negative (-0.00721) and only modestly contracting—bearish momentum is easing but not flipped. RSI(6)=44.83 is neutral-to-soft, not signaling an oversold bounce. Key levels: Pivot 3.543 (price ~3.54 is essentially at pivot), support S1=3.41 then S2=3.327; resistance R1=3.677 then R2=3.76. For an impatient buyer, there is no confirmed breakout; upside first requires clearing ~3.68–3.76, while a slip below 3.41 raises the odds of continuation lower.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
could trigger technical momentum buyers. Slightly call-leaning open interest (OI put/call <
is a modest positive.
Clear bearish technical structure (bearish MA stack; MACD still below zero). Pattern-based outlook provided is negative for the next week/month (-13.06% next week, -15.9% next month). No supportive news catalysts in the past week. Options IV is very high, reflecting elevated uncertainty. Hedge funds and insiders show no significant bullish accumulation (both neutral).
Latest reported quarter: 2025/Q3. Revenue fell to 77.725M (-1.79% YoY). Profitability deteriorated: net income was -6.414M (down -297.78% YoY) and EPS -0.08 (down -366.67% YoY). Gross margin declined to 41.36% (-9.16% YoY). Overall, growth is negative and margins/profits worsened, which weakens the case for an immediate long entry.
Recent analyst actions are net-negative: multiple price target cuts following Q3. UBS cut PT to $4 from $5.75 (Neutral). Morgan Stanley cut PT to $4 from $5 (Equal Weight), highlighting mix shift/discounting and more ACH/check mix impacting growth. DA Davidson maintained Buy but cut PT to $9 from $10, citing mixed Q3 and trimmed FY25 commentary while expecting better growth in 2026. Wall Street pros: potential 2026 re-acceleration and political media spend tailwind. Cons: near-term growth/mix pressure, recent guidance tone softening, and repeated PT reductions.
